tirzepatide surpass cvot 🫀 EASD 2025: (SURPASS-CVOT) Dulaglutide head-to-head showdown: ✓ Noninferior for MACE ✓ 16% ↓ all-cause mortality ✓ Superior in A1C & weight loss Tirzepatide confirms its broad cardiometabolic edge. #EASD2025 # Tirzepatide #GLP1 SURPASS-CVOT trial: For patients with

10 (3), 349 (2018) D.D

Think of it as a workout enhancer

Common Side Effects Nausea and vomiting Diarrhea or constipation Abdominal pain or discomfort Mild headache Indigestion or heartburn Less Common Side Effects Fatigue or dizziness Swelling at the injection site Temporary appetite changes Serious Side Effects and Warnings Monitoring Tips While Using Semanat Injection Check blood sugar regularly to prevent hypoglycemia

If youre unsure whether the medication was stored properly or you notice the liquid is discolored or feels warm or frozen, do not use it

The Growing Demand for Research-Grade Peptides As peptide research expands globally, the demand for high-quality, well-characterized compounds continues to rise

Keeping glucose tablets accessible provides quick correction if needed